Nitrophenols

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease

Retrieved on: 
Wednesday, July 10, 2019
Phenols, Aromatic compounds, Chemical compounds, Catechols, Nitrophenols, Neurocrine Biosciences, Opicapone, Catecholamines, Catechol-O-methyltransferase, Bial, Parkinson's disease, Neurocrine

With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.

Key Points: 
  • With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.
  • We look forward to working with the FDA to bring this new treatment option to patients coping with this debilitating disorder."
  • Neurocrine Biosciences in-licensed opicapone from BIAL in 2017 and has exclusive development and commercialization rights in the U.S. and Canada.
  • Opicapone, an investigational treatment for Parkinson's disease in the U.S., is a novel, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor.

The Global Market for Parkinson's Disease Drugs to 2024 - COMT (Catechol-O-Methyltransferase) Inhibitors to Register Robust Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 10, 2019
Health, Pharmaceutical, Aromatic compounds, Organic compounds, Catechols, Catechol-O-methyltransferase inhibitor, Nitrophenols, Catechol-O-methyltransferase, Tolcapone, Entacapone, Parkinson's disease, Pharmacological treatment of Parkinson's disease, Carbidopa/levodopa/entacapone

The "Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.
  • Parkinson's disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson's disease, with the growth in aging population levels.
  • The two most common COMT inhibitors, used in the treatment of Parkinson's disease, are Comtan (entacapone) and Tasmar (tolcapone).
  • The sheer number of Parkinson's disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market.